you are here: Home News Gilead

Gilead

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term
Lupin: Focus on inhalation and bio-similars to aid margins in medium term
COVID-19 update: Gilead announces steps to boost remdesivir production in India, donates 4.5 lakh vials
European Union executive signs remdesivir deal with Gilead
Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations
US group raises pricing recommendation for Gilead's remdesivir in COVID-19
COVID-19 treatment | Gilead to begin clinical trials of inhaled version of remdesivir
Gilead targets remdesivir supply for two million COVID-19 patients by year-end
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy
BDR Pharmaceuticals seeks drug controller’s nod to manufacture generic version of Remdesivir, irks Gilead: Report
Explained | COVID-19: Gilead licensing agreement of Remdesivir
U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19
Coronavirus pandemic | Gilead could face compulsory licensing despite patents if supply fails demand: Report
Gilead in talks to expand global supply of COVID-19 drug remdesivir
Laurus Labs Q4: Improving product mix and strong execution drive growth
Gilead's Remdesivir meets main goal of trial in COVID-19 patients
COVID-19 drug | India not keen to ask Gilead to issue compulsory licence: Report
Gilead disputes report that its drug flopped in leaked coronavirus trial
Institutional investors tell Big Pharma to cooperate on coronavirus
Gilead shares surge after report says COVID-19 patients respond to remdesivir
Coronavirus pandemic| Under pressure, Gilead says will try to make remdesivir affordable
Natco net profit surges five-fold to Rs 195 crore in Q3
Mylan launches generic hepatitis C drug MyHep in India
Hope for Hepatitis C-affected Indians
Cadila Health up 3%, diabetic drug gets tentative USFDA nod

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Gilead

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

COVID-19 update: Gilead announces steps to boost remdesivir production in India, donates 4.5 lakh vials

European Union executive signs remdesivir deal with Gilead

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

US group raises pricing recommendation for Gilead's remdesivir in COVID-19

COVID-19 treatment | Gilead to begin clinical trials of inhaled version of remdesivir

Gilead targets remdesivir supply for two million COVID-19 patients by year-end

GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy

BDR Pharmaceuticals seeks drug controller’s nod to manufacture generic version of Remdesivir, irks Gilead: Report

Explained | COVID-19: Gilead licensing agreement of Remdesivir

U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19

Coronavirus pandemic | Gilead could face compulsory licensing despite patents if supply fails demand: Report

Gilead in talks to expand global supply of COVID-19 drug remdesivir

Laurus Labs Q4: Improving product mix and strong execution drive growth

Gilead's Remdesivir meets main goal of trial in COVID-19 patients

COVID-19 drug | India not keen to ask Gilead to issue compulsory licence: Report

Gilead disputes report that its drug flopped in leaked coronavirus trial

Institutional investors tell Big Pharma to cooperate on coronavirus

Gilead shares surge after report says COVID-19 patients respond to remdesivir

Coronavirus pandemic| Under pressure, Gilead says will try to make remdesivir affordable

Natco net profit surges five-fold to Rs 195 crore in Q3

Mylan launches generic hepatitis C drug MyHep in India

Hope for Hepatitis C-affected Indians

Cadila Health up 3%, diabetic drug gets tentative USFDA nod